To the best of our knowledge, a comprehensive evaluation of the clinicopathologic characteristics of ER+/PgR–/HER2- breast cancer in relation to ER+/PgR+/HER2- tumours has not been published since the release of the 2013 St Gallen guidelines. Here, ERBB2 is linked to breast cancer.